Specialists of the department have undergone training in leading European, American and Asian oncological centers, including courses on laparoscopic and robot-assisted surgery. Annually, surgeons of the department participate in the most significant events in Russia, Europe and other countries. The head of the department, Prof. Valentina Nechushkina has organized more than 20 training events in Russia and in Europe.
Specialists of the department are members and chairmen of expert groups for the development of clinical recommendations for gynecologic oncology of the Russian Society of Clinical Oncology (RUSSCO) – the leading professional community of oncologists in the Russian Federation.
THE DEPARTMENT FOCUSES ON:
Primary diagnosis of precancer and malignant diseases of female:
Cytological examination of smears and punctates (including liquid-based cytology);
Tumor markers tests;
Computed tomography (CT);
Magnetic resonance imaging (MRI);
Positron emission tomography (PET).
Surgeries of various complexity by vaginal, laparoscopic and laparotomic approach;
Postoperative follow-up care;
Organ-sparing treatment of patients with cervical and ovarian cancer;
Primary cytoreductive surgery;
Surgical treatment of cervical cancer of the I-II stages without radiation therapy.
ABOUT THE DEPARTMENT:
Highly qualified specialists of the department provide treatment using the most modern methods and equipment, efficiently and in the shortest possible time.
Our department is the leader in Russia in organ-sparing treatment of cervical cancer with the size of the primary tumor more than 2 cm. Implementation of extended trachelectomy by our department shoots high fertility-sparing outcomes.
Our Department is one of the few in the world that specialize in primary cytoreductive surgery for disseminated ovarian cancer. The results of these operations are comparable with the results of the best centers of the USA and Europe.
80% of procedures performed at the first stage of cancer were effective for optimal cytoreduction (the size of the residual tumor was less than 1 cm) and 70% of surgeries - for complete cytoreduction (the residual tumor was not apparent macroscopically).